68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer.
Matthew John RobertsAndrew MortonPeter DonatoSamuel KyleDavid A PattisonPaul A ThomasGeoff CoughlinRachel EslerNigel DunglisonRobert A GardinerSuhail A R DoiLouise EmmettJohn YaxleyPublished in: European journal of nuclear medicine and molecular imaging (2020)
Intraprostatic 68Ga-PSMA-11 intensity is prognostic and may be a valuable new biomarker in localised prostate cancer, especially in men with biopsy-proven Gleason 3 + 4 disease considering an initial approach of active surveillance or focal therapy.